Cloudbreak Pharma’s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial
Cloudbreak Pharma Inc. is pleased to announce that our pipeline CBT-001, the global innovative ophthalmic drug for the treatment of pterygium has recently completed the enrollment of all patients in global centers in its international multicenter Phase III clinical trial. This study is a randomized, double-blind, placebo-controlled Phase III clinical trial, planning to enroll 660 […]
Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States
Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has completed the Phase II clinical trial investigating CBT-004 for the treatment of vascularized pinguecula in the United States in April. Preliminary results demonstrated excellent ocular and systemic safety profile. The […]
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium 6 August 2024 – Osaka, Japan – Santen Pharmaceutical Co., Ltd. (head office: Osaka, Japan; hereinafter Santen), a specialist in ophthalmology, and Cloudbreak Pharma Inc. (head office: California, US; hereinafter Cloudbreak), a clinical stage ophthalmic drug company, announce the […]
